University of Chicago’s Polsky Center for Entrepreneurship has formed microbiome-focused Avnovum Therapeutics, BiomeSense, Covira and Oxalo Therapeutics over the past year.

Spun out of Tübingen, Justus Liebig University Gießen and Münster, Atriva Therapeutics has raised an initial $1.4m to progress next-generation antiviral drugs for conditions including influenza.

The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.

Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.

Based on research from the universities of Bristol and Nottingham, Exonate has now raised $9m to develop a topical eye drop for conditions including diabetic macular edema.

Minnesota-founded microbial analysis spinout CoreBiome has been bought by medical diagnostics firm OraSure Technology after raising $1.4m from investors including Minnesota’s Discovery Capital fund.

Lidar technology developer Baraja has lured the support of Csiro's Innovation Fund as it pursues additional business for its autonomous vehicle perception system in the US and Asia.

Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.

A roundup of all the latest news on www.globaluniversityventuring.com for our subscribers.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.